DrugStoc and the Cost of Turning Procurement Into Infrastructure

A pharmacist in Ibadan does not open a procurement app because she wants software. She opens it because the alternative is a phone call to a rep who may or may not answer, followed by a wait of unknown length, followed by a delivery that may or may not match what she ordered. DrugStoc's B2B platform exists to remove that uncertainty, and its public record — funding filings, founder interviews, and its own product pages — describes a company that understood early on that the software was the easy part.

DrugStoc was incorporated in 2015 by Chibuzo Opara and Adham Yehia, according to Techpoint Africa's profile of the company, which also records that the founders spent twelve to eighteen months managing pharmaceutical sourcing for twenty facilities on spreadsheets before building anything resembling a platform. That detail matters more than it looks. It means the product was reverse-engineered from a real operating headache rather than designed toward a market opportunity, which is the more durable way to build in a market this fragmented.

What the company sells, and what it actually had to build

The visible product is a catalogue: DrugStoc's app listing describes pharmacies and hospitals browsing more than 10,000 medicines and healthcare products, placing wholesale orders, and tracking them through delivery. That is the part that looks like e-commerce. The part that isn't visible from the app icon is what Techpoint's profile calls the "experience centres" — fulfilment warehouses the company started building in 2017, two years after incorporation, once it became clear that a searchable catalogue with no reliable warehouse behind it was just a prettier version of the phone call it was supposed to replace.

DrugStoc also sells the inverse of this relationship: its services page offers manufacturers route-to-market and distribution support, which means the company sits in the middle of the chain twice — once as the provider's procurement layer, once as the manufacturer's distribution layer. Sitting on both sides of a trade is a classic way to capture margin in a fragmented market, and it is also a classic way to accumulate operational complexity that never shows up on the marketing page.

The mechanism: aggregation first, fulfilment second, retention third

The distribution logic runs in three steps once you strip away the interface. First, digital aggregation: providers who used to be reached one at a time by field reps now enter through a shared catalogue, which is what let DrugStoc claim, in its 2021 Series A announcement covered by TechCrunch, that it was connecting 400 manufacturers to 3,200 healthcare facilities and reaching 14 million people. Those numbers are five years old as of this writing and should be treated as a snapshot of 2021 ambition rather than current scale, but the shape of the claim — many suppliers, many buyers, one interface — is the part that has held.

Second, physical fulfilment: the warehouses built from 2017 onward are what convert a catalogue click into a delivery a pharmacist can actually stock. Third, retention through workflow lock-in: Pillometer, the company's cloud-based pharmacy operating system, plus in-app order tracking and representative chat, gives a provider a reason to keep transacting inside DrugStoc's environment rather than treating it as one vendor among several. Software that manages a pharmacy's day-to-day operations is much stickier than software that only takes orders.

Where the model gets expensive

TechCrunch's 2021 coverage of the Series A round cited monthly revenue growth of over 1,500 percent across the prior three years and stated ambitions to grow from 14 million to roughly 100 million people served, expanding into sixteen additional Nigerian states and eventually other African markets. That kind of growth curve is achievable in a market this underserved. It is also the exact curve that turns working capital into the binding constraint, because every additional facility connected means more inventory sitting in a warehouse against orders that have not yet been paid for, and every new state means new transit routes and, per the same coverage, cold-chain investment for temperature-sensitive products.

This is where the DrugStoc story gets harder to read from the outside, because the company's more recent public footprint is thinner than a company of its ambition would suggest. Tracxn's company profile lists DrugStoc's total disclosed funding at $4.4 million — the same Series A from 2021 — with an employee count of 146 as of mid-2026 and no publicly disclosed Series B, despite the company having stated an intent to raise a larger round. A distribution business growing the way DrugStoc says it wants to grow needs balance-sheet capital that operating revenue alone cannot supply fast enough, and the absence of a follow-on round in the public record by 2026 is worth more scrutiny than the presence of one would be.

The honest reading is that the public record doesn't show a raise, which is not the same as DrugStoc having failed to make one. A five-year gap between disclosed rounds in a capital-intensive distribution business is still the kind of thing an operator should ask about rather than assume away.

There is a second constraint sitting underneath the capital question, and it gets less attention because it doesn't show up in a funding announcement: quality assurance at scale. A pharmacist ordering from DrugStoc is trusting that a listed product's source, batch and expiry are what the catalogue says they are, and that trust is cheap to build when the catalogue is small and hard to maintain once it grows past a few thousand SKUs sourced from hundreds of manufacturers. The UNDP's framing of Nigeria's pharmaceutical distribution problem names counterfeiting explicitly as one of the failures a more direct supply chain is meant to solve, which puts the audit trail behind each SKU on equal footing with delivery speed as the thing DrugStoc's credibility actually rests on. A platform that gets faster while its provenance data gets thinner has traded one form of buyer anxiety for another.

The decision this suggests for a Nigerian operator

If you are building distribution infrastructure in a fragmented market, the decision DrugStoc's record puts in front of you is sequencing: build the fulfilment capability before you sell the reliability promise, not after. DrugStoc's founders spent over a year running procurement manually before writing software, and did not build a fulfilment centre until two years after incorporation. That is slower than most founders would choose, and it is also probably why the company survived long enough to reach a Series A. The temptation in health distribution is to ship the catalogue first because it is the cheap, visible part, and to treat the warehouse as a scaling problem for later. DrugStoc's own history argues against that ordering: the catalogue without the warehouse is a different product that happens to look similar, not a lesser version of the same one, and it earns a much lower level of trust from a buyer who has been burned before.

What would change this read

The open question is capital, not product. DrugStoc's mechanism (aggregate, fulfil, retain through software) is sound and matches how the company has actually behaved since 2015. What would change the read is a confirmed Series B or growth-debt facility, which would suggest the company has resourced the inventory and cold-chain expansion its stated ambitions require. Its absence from the public record by mid-2026, five years after the Series A, would suggest the company has instead been managing growth against a tighter capital constraint than its 2021 messaging implied. That's not a failure, but it is a materially different company to model than the one described in that funding announcement. Either a funding disclosure or a credible report on current facility count and geographic coverage would settle it.

Sources consulted

• DrugStoc B2B ordering platform
• DrugStoc Pharmacy Partner app listing
• DrugStoc Pillometer product page
• DrugStoc manufacturer services page
• Techpoint Africa: DrugStoc company profile
• TechCrunch: DrugStoc secures $4.4M Series A, November 2021
• Tracxn: DrugStoc company profile